Neurofibromatosis Therapeutics Pipeline is Driven by Unmet Medical Needs: P&S Market Research

NEW YORK, Jan. 30, 2018 -- According to the study published by P&S Market Research, Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.

Access Report Summary with TOC on "Neurofibromatosis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at: https://www.psmarketresearch.com/market-analysis/neurofibromatoses-therapeutics-pipeline-analysis

Majority of the pipeline drug candidates are being developed to be administered by oral route. Celldex Therapeutics Inc. and Merck Co. Inc. are in the process of developing a monoclonal antibody drug candidate, CDX0158, and Pembrolizumab respectively for the treatment of NF. Lixte Biotechnology Holdings Inc. is in the process of developing two drug candidates, in the Pre-Clinical stage of development for the treatment of neurofibromatosis (NF). In September 2016, the USFDA granted Orphan Drug Designation to BXCL101, a drug candidate of BioXcel Therapeutics Inc. for the treatment of NF type 2.

Since there is no treatment available for NF, the growing medical needs of the people suffering from the disease are driving its therapeutics pipeline growth. High rate of recurrence/progression of the disease and poor long-term benefit of surgery can be viewed as a limitation of this treatment option.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/neurofibromatoses-therapeutics-pipeline-analysis/report-sample

The drugs being developed by the different pharmaceutical companies demonstrated positive clinical trial results which in-turn increasing their further development. For instance, In June 2014, Array BioPharma Inc. announced positive results of Phase I/II, combination of binimetinib and LEE011. Selumetinib being developed by the AstraZeneca plc. And it met primary endpoint as confirmed partial responses (tumor volume decreases from baseline of ≥20%) in 17 of the 24 children (71%) in Phase I study.

Some of the key players developing drugs for the treatment of neurofibromatosis include Novartis AG, AstraZeneca Plc, Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc, BioXcel Therapeutics, Inc.

Related Research by P&S Market Research

Constipation Therapeutics – Pipeline Analysis 2017 - https://www.psmarketresearch.com/market-analysis/constipation-therapeutics-pipeline-analysis

Hereditary Angioedema (HAE) Therapeutics Pipeline Analysis 2017 - https://www.psmarketresearch.com/market-analysis/hereditary-angioedema-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.

With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com 

Connect with us: LinkedIn | Twitter | Google + | Facebook